Search

Your search keyword '"Li, Linzhao"' showing total 22 results
Start Over Author "Li, Linzhao"
22 results on '"Li, Linzhao"'

3. Visible light-induced recyclable porous g-C3N4 promoted one-pot alcohol oxidation–Wittig tandem reactions.

Author

Li, Linzhao, Ma, Zhongjie, Li, Cong, Chen, Gaoli, and Gao, Taiping

Subjects
*SUSTAINABLE chemistry, *TRANSITION metal catalysts, *HETEROGENEOUS catalysis, *PRECIOUS metals, *OXIDIZING agents
Abstract

Merging heterogeneous catalysis with one-pot tandem reactions serves as a key foundation for practical and sustainable chemistry. Herein, via rational design, porous graphite-phase carbon nitride (porous g-C3N4) was facilely synthesized via a soft template method. Compared to bulk g-C3N4, the larger specific surface area, excellent visible light response capability, and faster electron–hole migration rate enable porous g-C3N4 to exhibit outstanding catalytic performance in the visible light-induced one pot alcohol oxidation–Wittig tandem reactions. This protocol circumvents the use of expensive transition metal catalysts and toxic oxidizing agents, establishing a green and efficient system that facilitates the synthesis of α,β-unsaturated esters. Potentially, g-C3N4 emerges as a promising alternative to noble metal photocatalysts, thereby broadening the horizons of photocatalysis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Regulating Tumor-Associated Macrophage Polarization by Cyclodextrin-Modified PLGA Nanoparticles Loaded with R848 for Treating Colon Cancer

Author

Yuan, Haohua, primary, Gui, Huan, additional, Chen, Shuanghui, additional, Zhu, Lan, additional, Wang, Chenglv, additional, Jing, Qianyu, additional, Lv, Hang, additional, Wan, Quan, additional, Wang, Shuyi, additional, Zhou, Shengwen, additional, Ren, Xiaodong, additional, Nie, Yingjie, additional, and Li, Linzhao, additional

Published
2024
Full Text
View/download PDF

5. Inhibitors and PROTACs of CDK2: challenges and opportunities

Author

Zeng, Yangjie, Ren, Xiaodong, Jin, Pengyao, Fan, Zhida, Liu, Mengguang, Zhang, Yali, Li, Linzhao, Zhuo, Ming, Wang, Jubo, Li, Zhiyu, and Wu, Min

Abstract

ABSTRACTIntroductionAbundant evidence suggests that the overexpression of CDK2-cyclin A/E complex disrupts normal cell cycle regulation, leading to uncontrolled proliferation of cancer cells. Thus, CDK2 has become a promising therapeutic target for cancer treatment. In recent years, insights into the structures of the CDK2 catalytic site and allosteric pockets have provided notable opportunities for developing more effective clinical candidates of CDK2 inhibitors.Area coveredThis article reviews the latest CDK2 inhibitors that have entered clinical trials and discusses the design and discovery of the most promising new preclinical CDK2 inhibitors in recent years. Additionally, it summarizes the development of allosteric CDK2 inhibitors and CDK2-targeting PROTACs. The review encompasses strategies for inhibitor and PROTAC design, structure-activity relationships, as well as in vitro and in vivo biological assessments.Expert opinionDespite considerable effort, no CDK2 inhibitor has yet received FDA approval for marketing due to poor selectivity and observed toxicity in clinical settings. Future research must prioritize the optimization of the selectivity, potency, and pharmacokinetics of CDK2 inhibitors and PROTACs. Moreover, exploring combination therapies incorporating CDK2 inhibitors with other targeted agents, or the design of multi-target inhibitors, presents significant promise for advancing cancer treatment strategies.

Published
2024
Full Text
View/download PDF

6. Regulating Tumor-Associated Macrophage Polarization by Cyclodextrin-Modified PLGA Nanoparticles Loaded with R848 for Treating Colon Cancer

Author

Yuan,Haohua, Gui,Huan, Chen,Shuanghui, Zhu,Lan, Wang,Chenglv, Jing,Qianyu, Lv,Hang, Wan,Quan, Wang,Shuyi, Zhou,Shengwen, Ren,Xiaodong, Nie,Yingjie, Li,Linzhao, Yuan,Haohua, Gui,Huan, Chen,Shuanghui, Zhu,Lan, Wang,Chenglv, Jing,Qianyu, Lv,Hang, Wan,Quan, Wang,Shuyi, Zhou,Shengwen, Ren,Xiaodong, Nie,Yingjie, and Li,Linzhao

Abstract

Haohua Yuan,1 Huan Gui,1 Shuanghui Chen,1 Lan Zhu,1 Chenglv Wang,1 Qianyu Jing,2 Hang Lv,1 Quan Wan,2 Shuyi Wang,1 Shengwen Zhou,1 Xiaodong Ren,1 Yingjie Nie,1,3 Linzhao Li1 1Medical College, Guizhou University, Guizhou Province, 550025, People’s Republic of China; 2School of Preclinical Medicine of Zunyi Medical University, Zunyi, Guizhou Province, 563000, People’s Republic of China; 3NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People’s Hospital, Guiyang, Guizhou Province, 550002, People’s Republic of ChinaCorrespondence: Yingjie Nie; Linzhao Li, Medical College of Guizhou University, Guiyang, Guizhou Province, 550025, People’s Republic of China, Tel +86-085188274013; +86-085188274016, Email nienyj@hotmail.com; lzli@gzu.edu.cnPurpose: This study aimed to develop a novel and feasible modification strategy to improve the solubility and antitumor activity of resiquimod (R848) by utilizing the supramolecular effect of 2-hydroxypropyl-beta-cyclodextrin (2-HP-β-CD).Methods: R848-loaded PLGA nanoparticles modified with 2-HP-β-CD (CD@R848@NPs) were synthesized using an enhanced emulsification solvent-evaporation technique. The nanoparticles were then characterized in vitro by several methods, such as scanning electron microscopy (SEM), differential scanning calorimetry (DSC), Fourier transform infrared (FTIR) spectroscopy, particle size analysis, and zeta potential analysis. Then, the nanoparticles were loaded with IR-780 dye and imaged using an in vivo imaging device to evaluate their biodistribution. Additionally, the antitumor efficacy and underlying mechanism of CD@R848@NPs in combination with an anti-TNFR2 antibody were investigated using an MC-38 colon adenocarcinoma model in vivo.Results: The average size of the CD@R848@NPs was 376 ± 30 nm, and the surface charge was 21 ± 1 mV. Through this design, the targeting ability of 2-HP-β-CD can be leveraged and R848 is delivered to tumor-supporting M2-like macrophages in an effi

Published
2024

7. Ansofaxine hydrochloride inhibits tumor growth and enhances Anti-TNFR2 in murine colon cancer model

Author

Jing, Qianyu, primary, Wan, Quan, additional, Nie, Yujie, additional, Luo, Junqian, additional, Zhang, Xiangyan, additional, Zhu, Lan, additional, Gui, Huan, additional, Li, Linzhao, additional, Wang, Chenglv, additional, Chen, Shuanghui, additional, Wang, Mengjiao, additional, Yuan, Haohua, additional, Lv, Hang, additional, Pan, Runsang, additional, Jing, Qianjun, additional, and Nie, Yingjie, additional

Published
2023
Full Text
View/download PDF

8. Combined use of TLR4 and TLR7/8 agonists to improve the efficacy of immune checkpoint inhibitors in “hot” tumor treatment and the establishment of long-term immune protection

Author

Wang, Mengjiao, primary, Wan, Quan, additional, Wang, Chenglv, additional, Jing, Qianyu, additional, Nie, Yujie, additional, Zhang, Xiangyan, additional, Chen, Xin, additional, Yang, De, additional, Pan, Runsang, additional, Li, Linzhao, additional, Zhu, Lan, additional, Gui, Huan, additional, Chen, Shuanghui, additional, Deng, Yuezhen, additional, Chen, Tao, additional, and Nie, Yingjie, additional

Published
2023
Full Text
View/download PDF

11. Anti-TNFR2 enhanced the antitumor activity of a new HMGN1/3M-052 stimulated dendritic cell vaccine in a mouse model of colon cancer

Author

Zhu, Lan, primary, Zhang, Xiangyan, additional, Chen, Xin, additional, Yang, De, additional, Nie, Yujie, additional, Pan, Runsang, additional, Li, Linzhao, additional, Wang, Chenglv, additional, Gui, Huan, additional, Chen, Shuanghui, additional, Jing, Qianyu, additional, Wang, Mengjiao, additional, and Nie, Yingjie, additional

Published
2023
Full Text
View/download PDF

14. Pantothenate Kinase 1 Inhibits the Progression of Hepatocellular Carcinoma by Negatively Regulating Wnt/β-catenin Signaling

Author

Zi, Yuyuan, primary, Gao, Jie, additional, Wang, Chenglv, additional, Guan, Yidi, additional, Li, Linzhao, additional, Ren, Xinxin, additional, Zhu, Lan, additional, Mu, Yun, additional, Chen, Shuang-hui, additional, Zeng, Zimei, additional, Cao, Zhen, additional, Rong, Zhuoxian, additional, Chen, Pan, additional, Zhang, Xiuping, additional, Chen, Tao, additional, Xin, Haiguang, additional, Li, Xuebing, additional, Li, Zhi, additional, Sun, Lunquan, additional, Deng, Yuezhen, additional, Li, Nan, additional, and Nie, Yingjie, additional

Published
2022
Full Text
View/download PDF

15. Mesenchymal stromal cells protect hepatocytes from lipotoxicity through alleviation of endoplasmic reticulum stress by restoring SERCA activity

Author

Li, Linzhao, primary, Zeng, Xin, additional, Liu, Zhenzhen, additional, Chen, Xuanming, additional, Li, Lan, additional, Luo, Ruixi, additional, Liu, Xiaohong, additional, Zhang, Jie, additional, Liu, Jingping, additional, Lu, Yanrong, additional, Cheng, Jingqiu, additional, and Chen, Younan, additional

Published
2021
Full Text
View/download PDF

22. Mesenchymal stem cells alleviate palmitic acid-induced endothelial-to-mesenchymal transition by suppressing endoplasmic reticulum stress.

Author

Luo R, Li L, Liu X, Yuan Y, Zhu W, Li L, Liu J, Lu Y, Cheng J, and Chen Y

Subjects
Animals, Cell Survival drug effects, Cells, Cultured, Down-Regulation drug effects, Endothelium, Vascular physiology, Female, Human Umbilical Vein Endothelial Cells, Humans, Infant, Newborn, Male, Mesenchymal Stem Cells cytology, Pregnancy, Rats, Rats, Sprague-Dawley, Signal Transduction drug effects, Endoplasmic Reticulum Stress drug effects, Endothelium, Vascular drug effects, Epithelial-Mesenchymal Transition drug effects, Mesenchymal Stem Cells physiology, Palmitic Acid pharmacology
Abstract

High levels of plasma free fatty acids (FFAs) lead to endothelial dysfunction (ED), which is involved in the pathogenesis of metabolic syndrome, diabetes, and atherosclerosis. Endoplasmic reticulum (ER) stress and endothelial-to-mesenchymal transition (EndMT) are demonstrated to be mechanistically related to endothelial dysfunction. Mesenchymal stem cells (MSCs) have exhibited an extraordinary cytoprotective effect on cellular lipotoxicity and vasculopathy. However, the underlying mechanisms have not been clearly defined. In the present study, we investigated whether MSCs could ameliorate palmitic acid (PA)-induced endothelial lipotoxicity by reducing ER stress and EndMT. We observed that MSC cocultures substantially alleviated PA-induced lipotoxicity in human umbilical vein endothelial cells (HUVECs). MSCs were able to restore the cell viability, increase tubule formation and migration ability, and decrease inflammation response and lipid deposition. Furthermore, PA caused endothelial-to-mesenchymal transition in HUVECs, which was abrogated by MSCs possibly through inhibiting ER stress. In addition, PA stimulated MSCs to secrete more stanniocalcin-1 (STC-1). Knocking down of STC-1 in MSCs attenuated their effects on PA-induced lipotoxicity in HUVECs. In vivo, MSC transplantation alleviated dyslipidemia and endothelial dysfunction in high-fat diet-fed Sprague-Dawley rats. MSC-treated rats showed reduced expressions of ER stress-related genes in aortas and suppressed expressions of EndMT-related proteins in rat aortic endothelial cells. Overall, our findings indicated that MSCs were able to attenuate endothelial lipotoxicity through inhibiting ER stress and EndMT, in which STC-1 secreted from MSCs may play a critical role.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results